Cardio-Rheumatology Observatory · Pooled ATACC-RA Consortium

ATACC-RA Rheumatoid Arthritis EULAR 1.5x CV Risk Calculator

Systemic synovitis accounts for 30.4% of excess cardiovascular events unseen by general-population lipid scores. Recalibrate Framingham, ASCVD, or SCORE2 baseline output with EULAR weighting, prednisone hazard, and carotid plaque rules.

5,638 Pooled RA Cohort
30.4% RA-Attributable PAF
13 International Centers
Chiaroscuro medical exhibition still life of crimson arterial silk filament beside surgical brass calipers and smoked diagnostic glass against midnight obsidian
9.0% 10-Year Adjusted Risk
BORDERLINE / INTERMEDIATE (5.0%-9.9%) 1.50x EULAR Rule
Baseline: 6.0% Delta: +3.0%

Calibration Parameters

Client-Side / Zero Telemetry
Quick RA Case Presets
Source Population Equation
6.0%
Synovial Activity (DAS28)
Daily Oral Prednisone
Carotid Duplex / Coronary Calcium (CAC)
RA Modifiers & Safety Flags

EULAR 1.5x calibration shifts baseline 6.0% to 9.0% (intermediate band). Up to 42% of reclassified RA patients harbor silent carotid plaque.

ATACC-RA Urgent Bedside Checklist
  • [ ]Order bilateral carotid duplex ultrasound (bulb plaque) or CAC score before deferring statin therapy.
  • [ ]Repeat fasting lipid panel 8-12 weeks after achieving DAS28 remission to avoid lipid-paradox underestimation.
Open Full Multi-Variable Workbench & Threshold Guide →
Table 1: Standard Equation Misclassification vs. Observed 10-Year MACE

Uncorrected Framingham and ACC/AHA Pooled Cohort Equations underpredict 28% to 34% of observed 10-year cardiovascular events in rheumatoid arthritis because active inflammation suppresses LDL cholesterol while accelerating arterial plaque. Sources: Crowson et al., Ann Rheum Dis 2018 and Crowson et al., PLOS ONE 2017.

Population Equation Observed / Predicted RA Multiplier Impact on Statin Eligibility
Framingham Risk Score Underpredicts 34% 1.0x (Uncorrected) Delays primary lipid therapy when DAS28 > 3.2
ACC/AHA Pooled Cohort Underpredicts 28% None native Requires manual inflammatory risk-enhancer override
QRISK3 (RA Weighted) Calibrated 1.04 Built-in RA hazard Captures RA diagnosis and steroid exposure directly
EULAR + ATACC-RA Rule Target 0.98 1.5x (Universal RA) Reclassifies 11% of borderline cases into treat tier

Cumulative MACE Divergence (0-10 Years)

Observed ATACC-RA cardiovascular events diverge above Framingham predictions from Year 3 onward when active synovitis persists.

10-Year Cumulative MACE Incidence Divergence in Rheumatoid Arthritis Observed ATACC-RA (Seropositive / High CRP): 12.4% Predicted Framingham Baseline: 8.1% Yr 0 Yr 5 Yr 10

Preserved ATACC-RA Participating Centers

View All 13 Cohorts & Investigator Profiles →

Resolve Your Clinical Question

Interactive Cardio-Rheumatology Tools
01 / BORDERLINE SCORE

Should This Patient Start a Statin?

Combine Framingham, SCORE2, or QRISK3 with prednisone dose and carotid plaque overrides, then copy or print a clinic handover.

Open Risk Workbench →
02 / CHOLESTEROL REBOUND

Why Did LDL Rise After Starting Treatment?

Simulate how CRP suppression under MTX, TNFi, and tocilizumab reverses inflammation-driven hypolipidemia.

Decode Lipid Paradox →
03 / DRUG SELECTION

Is a JAK Inhibitor or Prednisone Safe Here?

Screen ORAL Surveillance age and smoking red flags and compare vascular hazard ratios across csDMARDs and biologics.

Run DMARD Safety Gate →
04 / VASCULAR IMAGING

Carotid Plaque & CAC Reclassification

Evaluate B-mode carotid duplex and Agatston calcium thresholds alongside preserved consortium citations.

Open Imaging Protocol →